📢 Exciting News! We successfully raised 6.5M euros in Round C financing! Thanks to our shareholders for their confidence in #OncoDNA's vision. Our objective: double-digit, profitable growth in #personalizedmedicine. Introducing the #OncoDEEPKit, empowering tailored solutions!
We are thrilled to unveil the exceptional quality of the OncoDEEP Kit's HRD assessment presented in our new article "Homologous Recombination Deficiency (#HRD) assessment for clinical management using the OncoDEEP Kit" => ow.ly/kBlk50NNI8n 💥
#labs#precisionmedicine
#OncoDNA se enorgullece de haber sido seleccionada en la Fase 1 del Procedimiento de Adquisición Pre-comercial de oncNGS con el objetivo de desarrollar una solución para el análisis por NGS de biopsias líquidas de pacientes oncológicos🧬
#oncodna#oncologiadeprecisión
Our merry team at @OncoDNA is sending their very best wishes for this holiday season🎄and wishing you a sparkling New Year🎉. We are grateful for the trust you have placed in us, and we hope to keep on bringing you closer to your dreams in the year to come✨.
OncoDNA is pleased to announce a transformational partnership with the Berkshire and Surrey Pathology Services to facilitate Private NGS testing across UK 🙌.
Discover all details in our press release: ow.ly/7xXU50LcM0n#oncodna#oncodeep#precisiononcology
We have launched our new #OncoDEEP Kit during the #ESMO in Paris. It enables laboratories with #NGS capabilities to support oncologists in finding the most effective and personalized treatments for their cancer patients🔬.
Discover all details: ow.ly/GErN50KI8ib